ProQR Therapeutics (PRQR) announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Highlights RNA Innovations in Upcoming Event
- ProQR Therapeutics price target raised to $8 from $5 at JMP Securities
- ProQR Therapeutics Highlights Q3 2024 Financial Results
- ProQR Therapeutics price target raised to $10 from $5 at H.C. Wainwright
- ProQR Therapeutics price target raised to $4 from $2.50 at Chardan